NASDAQ:AMAG - AMAG Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$15.31 -0.62 (-3.89 %)
(As of 02/22/2019 01:11 AM ET)
Previous Close$15.93
Today's Range$15.26 - $15.88
52-Week Range$14.35 - $26.10
Volume532,099 shs
Average Volume567,651 shs
Market Capitalization$528.75 million
P/E Ratio-3.95
Dividend YieldN/A
Beta0.45
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has an option agreement with Velo Bio LLC to acquire the rights to digoxin immune fab, a polyclonal antibody, which is in Phase IIb/IIIa trial for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Bremelanotide, an investigational product for the treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, offer for sale, and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Receive AMAG News and Ratings via Email

Sign-up to receive the latest news and ratings for AMAG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMAG
CUSIP00163U10
Phone617-498-3300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$474 million
Cash Flow$1.5099 per share
Book Value$21.62 per share

Profitability

Net Income$-65,760,000.00

Miscellaneous

Employees762
Market Cap$528.75 million
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable

AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions

What is AMAG Pharmaceuticals' stock symbol?

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) issued its earnings results on Thursday, February, 7th. The specialty pharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.38. The specialty pharmaceutical company had revenue of $88.10 million for the quarter, compared to analysts' expectations of $95.21 million. AMAG Pharmaceuticals had a negative net margin of 13.07% and a negative return on equity of 17.10%. The business's revenue was down 31.4% on a year-over-year basis. During the same quarter last year, the business earned $0.10 earnings per share. View AMAG Pharmaceuticals' Earnings History.

When is AMAG Pharmaceuticals' next earnings date?

AMAG Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for AMAG Pharmaceuticals.

What guidance has AMAG Pharmaceuticals issued on next quarter's earnings?

AMAG Pharmaceuticals updated its FY 2019 earnings guidance on Thursday, February, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $365-415 million, compared to the consensus revenue estimate of $382.51 million.

What price target have analysts set for AMAG?

10 Wall Street analysts have issued 1-year price objectives for AMAG Pharmaceuticals' stock. Their predictions range from $18.00 to $24.65. On average, they anticipate AMAG Pharmaceuticals' share price to reach $20.9650 in the next year. This suggests a possible upside of 36.9% from the stock's current price. View Analyst Price Targets for AMAG Pharmaceuticals.

What is the consensus analysts' recommendation for AMAG Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AMAG Pharmaceuticals in the last year. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AMAG Pharmaceuticals.

What are Wall Street analysts saying about AMAG Pharmaceuticals stock?

Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "In July, AMAG’s drug, Makena’s generic hit the market, which pulled down its sales. AMAG’s other drug Feraheme currently competes with IV iron replacement therapies like Venofer, Injectafer, Ferrlecit and their generic versions, among others. This could further limit sales. However, the company divested the Cord Blood Registry (CBR) business and strengthened its balance sheet;. It acquired AMAG-423, which is an orphan drug for the potential treatment of severe preeclampsia; and launched the Intrarosa direct-to-consumer campaign. AMAG is prepared for the upcoming FDA advisory committee meeting for Vyleesi (bremelanotide). Shares of the company have outperformed the industry year to date. Loss estimates have widenede ahead of the Q4 results. The company has mixed earnings surprise in the last few quarters." (1/23/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate the Neutral rating and adjust our PT to $18 (from $17) for AMAG stock. With the commercial potential of Intrarosa still unproven and the approvability of bremelanotide unknown, we believe investors will view the Makena franchise as the most significant supporter of share price value, particularly now that the CBR business is being divested. We suppose a bullish outlook could prevail over the near- to intermediate-term if Makena holds its own and no evidence emerges that Intrarosa or bremelanotide could disappoint expectations. We believe that the set up for 2019 has to be decidedly positive for the stock to perform well over the next 12-18 months absent, of course, transformational business activities." (8/3/2018)

Has AMAG Pharmaceuticals been receiving favorable news coverage?

News articles about AMAG stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AMAG Pharmaceuticals earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an impact on the company's share price in the immediate future.

Who are some of AMAG Pharmaceuticals' key competitors?

What other stocks do shareholders of AMAG Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AMAG Pharmaceuticals investors own include Celgene (CELG), Bausch Health Companies (BHC), Broadcom (AVGO), Gilead Sciences (GILD), Tesla (TSLA), Netflix (NFLX), Skyworks Solutions (SWKS), Energy Transfer LP Unit (ET), Alibaba Group (BABA) and bluebird bio (BLUE).

Who are AMAG Pharmaceuticals' key executives?

AMAG Pharmaceuticals' management team includes the folowing people:
  • Dr. William K. Heiden, CEO, Pres & Director (Age 59)
  • Mr. Edward H. Myles, Exec. VP & CFO (Age 47)
  • Mr. Joseph D. Vittiglio, Exec. VP of Legal Affairs and Quality, Gen. Counsel & Sec. (Age 47)
  • Dr. Julie Krop, Exec. VP of Devel. & Chief Medical Officer (Age 53)
  • Mr. Nicholas Grund, Exec. VP & Chief Commercial Officer (Age 49)

Who are AMAG Pharmaceuticals' major shareholders?

AMAG Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Robeco Institutional Asset Management B.V. (3.55%), D. E. Shaw & Co. Inc. (3.00%), Connor Clark & Lunn Investment Management Ltd. (2.02%), Royce & Associates LP (1.93%), Great Point Partners LLC (1.92%) and Acadian Asset Management LLC (1.57%). Company insiders that own AMAG Pharmaceuticals stock include Joseph Vittiglio, Julie Krop and William K Heiden. View Institutional Ownership Trends for AMAG Pharmaceuticals.

Which institutional investors are selling AMAG Pharmaceuticals stock?

AMAG stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Hourglass Capital LLC, Acadian Asset Management LLC, State Board of Administration of Florida Retirement System, Macquarie Group Ltd., GSA Capital Partners LLP, Voce Capital Management LLC and KBC Group NV. Company insiders that have sold AMAG Pharmaceuticals company stock in the last year include Joseph Vittiglio and William K Heiden. View Insider Buying and Selling for AMAG Pharmaceuticals.

Which institutional investors are buying AMAG Pharmaceuticals stock?

AMAG stock was bought by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Royce & Associates LP, Robeco Institutional Asset Management B.V., Canada Pension Plan Investment Board, Monashee Investment Management LLC, Two Sigma Investments LP, Squarepoint Ops LLC and Prudential Financial Inc.. View Insider Buying and Selling for AMAG Pharmaceuticals.

How do I buy shares of AMAG Pharmaceuticals?

Shares of AMAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AMAG Pharmaceuticals' stock price today?

One share of AMAG stock can currently be purchased for approximately $15.31.

How big of a company is AMAG Pharmaceuticals?

AMAG Pharmaceuticals has a market capitalization of $528.75 million and generates $474 million in revenue each year. The specialty pharmaceutical company earns $-65,760,000.00 in net income (profit) each year or ($3.88) on an earnings per share basis. AMAG Pharmaceuticals employs 762 workers across the globe.

What is AMAG Pharmaceuticals' official website?

The official website for AMAG Pharmaceuticals is http://www.amagpharma.com.

How can I contact AMAG Pharmaceuticals?

AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected]


MarketBeat Community Rating for AMAG Pharmaceuticals (NASDAQ AMAG)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  327 (Vote Outperform)
Underperform Votes:  433 (Vote Underperform)
Total Votes:  760
MarketBeat's community ratings are surveys of what our community members think about AMAG Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMAG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMAG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Featured Article: Percentage Gainers

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel